NEW YORK (GenomeWeb News) – VisEn Medical today said that the Swiss Federal Institute of Technology will use its portfolio of in vivo fluorescence probes and fluorescence molecular tomography imaging system in its molecular imaging programs.
 
VisEn said its technologies are designed to identify, characterize, and quantify a range of biological phenomena in vivo, including known molecular activities underlying disease states such as cancer, inflammation, cardiovascular disease, and bone disease.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.

Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.